Page last updated: 2024-09-04
docetaxel anhydrous and ldn 193189
docetaxel anhydrous has been researched along with ldn 193189 in 1 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (ldn 193189) | Trials (ldn 193189) | Recent Studies (post-2010) (ldn 193189) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 113 | 0 | 106 |
Protein Interaction Comparison
Protein | Taxonomy | docetaxel anhydrous (IC50) | ldn 193189 (IC50) |
---|---|---|---|
Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | 0.0245 | |
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.4856 | |
Bone morphogenetic protein 4 | Homo sapiens (human) | 0.0049 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4314 | |
Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | 0.0124 | |
Activin receptor type-1B | Homo sapiens (human) | 0.7218 | |
TGF-beta receptor type-1 | Homo sapiens (human) | 0.431 | |
Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | 0.0147 | |
TGF-beta receptor type-2 | Homo sapiens (human) | 0.1482 | |
Dual specificity protein kinase CLK2 | Homo sapiens (human) | 0.4856 | |
5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | 0.4856 | |
Activin receptor type-1 | Homo sapiens (human) | 0.2081 | |
Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | 3.845 | |
5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | 0.6129 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Other Studies
1 other study(ies) available for docetaxel anhydrous and ldn 193189
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |